+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Interaction between Adrenergic Agonists and Forskolin on Adenylate Cyclase Activity in the Rabbit Proximal Tubule

      , ,

      Kidney and Blood Pressure Research

      S. Karger AG

      cAMP, Kidney, Adrenergic receptors, Forskolin, Proximal tubule

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Using a micro-radioimmunoassay, cAMP was measured in single, isolated S2 proximal straight tubules dissected from rabbit kidneys to investigate the effects of adrenergic agonists on adenylate cyclase activity. The baseline activity of adenylate cyclase was low and unaffected by either the α<sub>2</sub> agonist clonidine, the β agonist isoprenaline (in the absence or presence of 1 µ M forskolin) or 1 µ M forskolin. Adenylate cyclase activity was markedly stimulated by 20 µ M forskolin, an effect which was inhibited by 1 µ M clonidine. The inhibition by clonidine was not apparent in the presence of the α<sub>2</sub> antagonist yohimbine. These results confirm the inability of isoprenaline to stimulate adenylate cyclase in the rabbit proximal tubule and demonstrate the coupling of α<sub>2</sub> receptors, in an inhibitory fashion, to adenylate cyclase. The inhibitory action of the α<sub>2</sub>-receptor agonist was independent of other hormone activity in the renal proximal tubule.

          Related collections

          Author and article information

          Kidney Blood Press Res
          Kidney and Blood Pressure Research
          S. Karger AG
          11 November 2008
          : 18
          : 5
          : 231-236
          School of Biological Sciences, University of Manchester, UK
          173920 Renal Physiol Biochem 1995;18:231–236
          © 1995 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Original Paper

          Cardiovascular Medicine, Nephrology

          Kidney, Proximal tubule, Adrenergic receptors, cAMP, Forskolin


          Comment on this article